Comparative Pharmacology
Head-to-head clinical analysis: ATARAX versus VISTARIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATARAX versus VISTARIL.
ATARAX vs VISTARIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydroxyzine is a piperazine derivative with antihistaminic (H1-receptor antagonist) and anticholinergic properties; also exhibits sedative, anxiolytic, and antiemetic effects due to suppression of activity in subcortical areas of the CNS.
Hydroxyzine is a piperazine derivative antihistamine that acts as a competitive antagonist of histamine H1 receptors, thereby suppressing histamine activity in the subcortical area of the central nervous system. It also has anxiolytic, sedative, antiemetic, and antispasmodic effects.
25 mg orally 3-4 times daily; maximum 100 mg per day. Also available as 50 mg intramuscular injection every 4-6 hours.
Oral: 50-100 mg 4 times daily; IM: 25-100 mg every 4-6 hours as needed.
None Documented
None Documented
Terminal elimination half-life is approximately 20-25 hours in healthy adults; may be prolonged in elderly, hepatic impairment, or renal insufficiency (up to 30-40 hours); steady-state achieved within 3-4 days.
Terminal elimination half-life: 20-25 hours in adults; prolonged in hepatic impairment or elderly; steady-state achieved in ~4-5 days.
Primarily hepatic metabolism via CYP3A4 and CYP2D6; renal excretion of metabolites accounts for approximately 70-80% of the dose, with less than 1% excreted unchanged; fecal excretion is about 10-15%.
Primarily hepatic metabolism; <1% excreted unchanged in urine; biliary/fecal elimination of metabolites accounts for approximately 50-60% of total clearance.
Category C
Category C
Antihistamine
Antihistamine